ArticleOncogene2026
Hypoxia-induced XBP1s-MYDGF axis suppresses ferroptosis through UBQLN1-mediated stabilization of LCN2 in gastric cancer.
Article in Oncogene, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Translating the Crosstalk Between Unfolded Protein Response and Ferroptosis to Cancer Therapies.Current oncology reports · 2026Review
- A recurrently perturbed 12-gene program marks drug-tolerant persister states across cancer types.Frontiers in bioinformatics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Solid tumors such as gastric cancers exploit hypoxia-induced adaptive mechanisms to evade cell death. Here, we identify a hypoxia-triggered signaling axis in which the spliced form of XBP1s transcriptionally activates MYDGF. We demonstrate that MYDGF competitively binds the ubiquitin adaptor protein UBQLN1 at the STI1-4 domain, thereby blocking UBQLN1-mediated recognition and endoplasmic reticulum-associated degradation (ERAD) of LCN2. Stabilized LCN2 sequesters redox-active iron and inhibits iron-dependent lipid peroxidation, thereby suppressing ferroptosis. Hypoxia promotes the splicing of XBP1s, which directly binds to the MYDGF promoter, increasing its expression. Genetic disruption of this axis sensitizes gastric cancer cells to ferroptosis inducers both in vitro and in vivo. These findings reveal a previously unrecognized mechanism of hypoxia-induced ferroptosis resistance and suggest that the XBP1-MYDGF-UBQLN1-LCN2 pathway is a therapeutic target for hypoxic tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.